Get your full text copy in PDF
Daisuke Takarabe, Tetsuro Tsujimoto, Miyako Kishimoto, Mitsuhiko Noda
(Department of Endocrinology and Metabolism, Tama-Hokubu Medical Center, Tokyo, Japan)
Med Sci Case Rep 2015; 2:53-57
Repaglinide is typically administered 3 times daily before meals. However, treatment regimens for elderly patients should be simplified as much as possible.
CASE REPORT: We report the cases of 2 elderly patients with type 2 diabetes (T2D) admitted to the hospital for glycemic control. Using continuous glucose monitoring, we monitored the effects of a twice-daily dosage of repaglinide compared with 3-times-daily dosage in the patients. In patient 1, we observed some worsening of glycemic control during the twice-daily treatment period, compared with the effects during the 3-times-daily treatment period. However, in patient 2, we did not observe any apparent worsening of that.
CONCLUSIONS: In some patients, the twice-daily dosage of repaglinide may be useful for their glycemic control to reach target.